Table 1 Summary of EORTC QLQ-C30 data collected in the CLARINET study and the number of successful mappings to EQ-5D-based utility values
All patients | Lanreotide | Placebo | ||
|---|---|---|---|---|
ITT population | 204 | 101 | 103 | |
Total assessments | 1088 | 559 | 529 | |
Assessments per patient | Mean | 5.5 | 5.1 | 5.5 |
Median (Min–Max) | 7 (1–8) | 5 (1–7) | 7 (1–8) | |
Mapped to EQ-5D using McKenzie algorithm [16] (N, %) | 1053 (96.8%) | 540 (96.6%) | 513 (97.0%) | |
Mapped to EQ-5D using Longworth algorithm [15] (N, %) | 1041 (95.7%) | 530 (94.8%) | 511 (96.6%) | |